Justin Walsh
Stock Analyst at Jones Trading
(0.96)
# 3,788
Out of 4,955 analysts
41
Total ratings
36.11%
Success rate
-10.04%
Average return
Main Sectors:
Stocks Rated by Justin Walsh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| YMAB Y-mAbs Therapeutics | Downgrades: Hold | n/a | $8.54 | - | 2 | Aug 5, 2025 | |
| THTX Theratechnologies | Downgrades: Hold | n/a | $3.26 | - | 3 | Jul 3, 2025 | |
| LNTH Lantheus Holdings | Maintains: Buy | $122 → $109 | $59.39 | +83.53% | 9 | Jun 23, 2025 | |
| VNRX VolitionRx | Initiates: Buy | $3 | $0.68 | +341.24% | 1 | Jun 10, 2025 | |
| BLRX BioLineRx | Upgrades: Buy | $12 | $3.61 | +232.41% | 3 | May 30, 2025 | |
| CLNN Clene | Initiates: Buy | $30 | $5.42 | +453.51% | 1 | Apr 23, 2025 | |
| MNPR Monopar Therapeutics | Downgrades: Hold | n/a | $32.47 | - | 1 | Apr 2, 2025 | |
| SER Serina Therapeutics | Initiates: Buy | $11 | $5.35 | +105.61% | 1 | Mar 11, 2025 | |
| ANRO Alto Neuroscience | Initiates: Buy | $18 | $3.59 | +401.39% | 1 | Dec 16, 2024 | |
| RAPP Rapport Therapeutics | Initiates: Buy | $42 | $14.95 | +180.94% | 1 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $22 | $3.62 | +508.58% | 2 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $4.96 | +222.58% | 1 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $2.99 | +568.90% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $4 | $0.85 | +370.59% | 4 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $3.29 | +507.90% | 1 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $2.13 | +745.07% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $440 | $1.76 | +24,900.00% | 1 | Feb 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $0.49 | +15,206.12% | 1 | Oct 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $20 | $37.77 | -47.05% | 1 | May 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $440 → $200 | $1.60 | +12,400.00% | 2 | Apr 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $2.82 | +254.61% | 1 | Jan 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $800 | $8.86 | +8,929.35% | 1 | Sep 2, 2021 |
Y-mAbs Therapeutics
Aug 5, 2025
Downgrades: Hold
Price Target: n/a
Current: $8.54
Upside: -
Theratechnologies
Jul 3, 2025
Downgrades: Hold
Price Target: n/a
Current: $3.26
Upside: -
Lantheus Holdings
Jun 23, 2025
Maintains: Buy
Price Target: $122 → $109
Current: $59.39
Upside: +83.53%
VolitionRx
Jun 10, 2025
Initiates: Buy
Price Target: $3
Current: $0.68
Upside: +341.24%
BioLineRx
May 30, 2025
Upgrades: Buy
Price Target: $12
Current: $3.61
Upside: +232.41%
Clene
Apr 23, 2025
Initiates: Buy
Price Target: $30
Current: $5.42
Upside: +453.51%
Monopar Therapeutics
Apr 2, 2025
Downgrades: Hold
Price Target: n/a
Current: $32.47
Upside: -
Serina Therapeutics
Mar 11, 2025
Initiates: Buy
Price Target: $11
Current: $5.35
Upside: +105.61%
Alto Neuroscience
Dec 16, 2024
Initiates: Buy
Price Target: $18
Current: $3.59
Upside: +401.39%
Rapport Therapeutics
Oct 18, 2024
Initiates: Buy
Price Target: $42
Current: $14.95
Upside: +180.94%
May 16, 2024
Maintains: Buy
Price Target: $15 → $22
Current: $3.62
Upside: +508.58%
May 10, 2024
Initiates: Buy
Price Target: $16
Current: $4.96
Upside: +222.58%
Apr 17, 2024
Initiates: Buy
Price Target: $20
Current: $2.99
Upside: +568.90%
Sep 7, 2023
Reinstates: Buy
Price Target: $4
Current: $0.85
Upside: +370.59%
Sep 6, 2023
Initiates: Buy
Price Target: $20
Current: $3.29
Upside: +507.90%
May 16, 2023
Initiates: Buy
Price Target: $18
Current: $2.13
Upside: +745.07%
Feb 10, 2023
Initiates: Buy
Price Target: $440
Current: $1.76
Upside: +24,900.00%
Oct 7, 2022
Initiates: Buy
Price Target: $75
Current: $0.49
Upside: +15,206.12%
May 20, 2022
Maintains: Buy
Price Target: $17 → $20
Current: $37.77
Upside: -47.05%
Apr 5, 2022
Maintains: Buy
Price Target: $440 → $200
Current: $1.60
Upside: +12,400.00%
Jan 19, 2022
Initiates: Buy
Price Target: $10
Current: $2.82
Upside: +254.61%
Sep 2, 2021
Initiates: Buy
Price Target: $800
Current: $8.86
Upside: +8,929.35%